Drugs / Parathyroid Hormone-related Protein (1-36)
Parathyroid Hormone-related Protein (1-36)
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00580788 | Jan 2008 → Dec 2009 | humoral hypercalcemia of malignancy, hyperparathyroidism, osteoporosis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01333267 | Jan 2015 → Jul 2017 | humoral hypercalcemia of malignancy, hyperparathyroidism, osteoporosis | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00853723 | May 2009 → Feb 2012 | osteoporosis | University of Pittsburgh | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Parathyroid Hormone-related Protein (1-36) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01333267 ↗ |
| Known as | hPTHrP(1-36) | “We therefore developed 7-day continuous-infusion models using human parathyroid hormone(1-34) [hPTH(1-34)] and human parathyroid hormone-related protein(1-36) [hPTHrP(1-36)] in...” PMID 21544866 ↗ Sep 2011 |
| Known as | PTHrP (1-36) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00580788 ↗ |
| Action | Activate | “Both peptides bind to the same receptor, PTH-1 R, and activate downstream signaling pathways” NCT00853723 ↗ |
| Modality | Protein / enzyme biologic | “human parathyroid hormone-related protein(1-36)” PMID 21544866 ↗ Sep 2011 |
| Route | Intravenous | “continuous intravenous manner” NCT00580788 ↗ |